Keywords: karo, bio, losses, rise, revenues, slump, sweden
Karo Bio losses rise and revenues slump
Article | 18 July 2005
Sweden's drug discovery group Karo Bio has reported a sharp decline in second-quarter 2005 (April-June) revenues to 2.7 million Swedish kronor ($343,980), down ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
